 | Review waiting, please be patient.
This may take 4 months or more, since drafts are reviewed in no specific order. There are 3,103 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
- Nucleix
- Nucleix** is a biotechnology company specializing in non-invasive molecular diagnostics for the early detection of cancer. The company focuses on leveraging epigenetic and genetic biomarkers to create innovative diagnostic solutions.
- History
Nucleix was founded in 2008 by Dr. Danny Frumkin, [Dr. Elon Ganor](https://en.wikipedia.org/wiki/Elon_Ganor), and Adam Wasserstrom in Israel. The company was established with the mission of developing advanced diagnostic tools to improve early cancer detection and patient outcomes. Over the years, Nucleix has received funding from various venture capital firms and grants to support its research and development activities.
- Technology
Nucleix employs proprietary technologies to analyze DNA methylation patterns and other epigenetic markers. The company’s main focus is on detecting cancer-specific biomarkers in bodily fluids, such as blood and urine, enabling non-invasive and early cancer detection.
- EpiCheck Platform
Nucleix’s flagship technology, the EpiCheck platform, utilizes a proprietary methylation-sensitive restriction enzyme technique to identify cancer-related epigenetic changes. This platform has been applied to develop several diagnostic tests, including: - **Bladder EpiCheck:** A urine test for the detection of bladder cancer recurrence. - **Lung EpiCheck:** A blood test under development for the early detection of lung cancer.
- Products
- Bladder EpiCheck
Bladder EpiCheck is a non-invasive urine test designed to monitor bladder cancer recurrence in patients. The test analyzes DNA methylation patterns in urine samples to detect the presence of cancer cells. Bladder EpiCheck has been clinically validated in multiple studies, is CE-marked, and received FDA 510(k) clearance for bladder cancer recurrence in the United States.
- Lung EpiCheck
Lung EpiCheck is a blood-based test aimed at the early detection of lung cancer. Currently in the development and validation stages, this test seeks to provide a non-invasive option for lung cancer screening and early diagnosis, potentially improving survival rates through earlier intervention.
- Research and Development
Nucleix is actively involved in research and development to expand its diagnostic portfolio. The company collaborates with leading academic institutions, hospitals, and research organizations to validate and improve its technologies. Ongoing projects include expanding the applications of the EpiCheck platform to other types of cancer and refining existing tests to enhance sensitivity and specificity.
- Partnerships and Collaborations
Nucleix has established partnerships with several key organizations in the biotechnology and healthcare sectors to advance its research and commercial goals. These collaborations facilitate access to clinical samples, regulatory expertise, and market channels, aiding the development and distribution of Nucleix’s diagnostic tests.
- Funding and Financials
Nucleix has secured funding from various sources, including venture capital firms and governmental grants. Notable investors include OrbiMed, Aurum Ventures, and the Israel Innovation Authority. The financial support has been instrumental in accelerating the company’s R&D efforts and bringing its products to market.
- Awards and Recognition
Nucleix has received several awards and accolades for its innovative contributions to cancer diagnostics. The company has been recognized in industry forums and by professional organizations for its groundbreaking work in molecular diagnostics and epigenetics.
- See Also
- Molecular diagnostics - Epigenetics - Cancer biomarkers - Non-invasive cancer detection
- References
1. [Nucleix Official Website](https://www.nucleix.com/) 2. ["Bladder EpiCheck: A Novel Urine Test for Monitoring Bladder Cancer." Journal of Urology. 2020.](https://www.auajournals.org/doi/abs/10.1097/JU.0000000000000312) 3. ["Early Detection of Lung Cancer Using Epigenetic Biomarkers." Cancer Research. 2021.](https://cancerres.aacrjournals.org/content/81/6/1675) 4. ["FDA grants 510(k) clearance to Bladder EpiCheck for NMIBC surveillance." Urology Times. 2023.](https://www.urologytimes.com/view/fda-grants-510-k-clearance-to-bladder-epicheck-for-nmibc-surveillance) 5. ["FDA clears Nucleix’s Bladder EpiCheck." Medical Device Network. 2023.](https://www.medicaldevice-network.com/news/fda-clears-nucleixs-bladder-epicheck/) 6. ["Nucleix’s Bladder EpiCheck® Receives FDA 510(k) Clearance." Business Wire. 2023.](https://www.businesswire.com/news/home/20230504006053/en/Nucleix%E2%80%99s-Bladder-EpiCheck%C2%AE-Receives-FDA-510-k-Clearance-for-Monitoring-of-Non-Muscle-Invasive-Bladder-Cancer-NMIBC-Recurrence)
- External Links
- [Nucleix on LinkedIn](https://www.linkedin.com/company/nucleix-ltd-/)